Location History:
- Frederick, MD (US) (2002 - 2010)
- Millers, MD (US) (2010)
Company Filing History:
Years Active: 2002-2010
Title: Alan L Schmaljohn: Innovator in Filovirus Research
Introduction
Alan L Schmaljohn is a prominent inventor based in Frederick, MD (US), known for his significant contributions to the field of virology. With a total of 10 patents to his name, Schmaljohn has made remarkable advancements in the development of vaccines and therapeutic agents against filoviruses, particularly Ebola and Marburg.
Latest Patents
Among his latest patents is the development of chimeric filovirus glycoproteins. These chimeric GP molecules were constructed by swapping subunits between the glycoprotein proteins of Ebola virus (EBOV) and Marburg virus (MBGV). The innovative design allows for high protein expression levels in mammalian cells, utilizing an alphavirus replicon as a vaccine vector. The results of his research demonstrated that these chimeric molecules provided full protection to guinea pigs against MBGV and EBOV challenges. This indicates that a protective epitope resides within the GP2 subunit of both the MBGV and EBOV GP proteins. Furthermore, Schmaljohn's work on generating virus-like particles has shown promise for their use as diagnostic and therapeutic agents, as well as a potential panfilovirus vaccine.
Career Highlights
Throughout his career, Schmaljohn has worked with esteemed organizations, including the U.S. Government as represented by the Secretary of the Army and the U.S. Army Medical Research Institute of Infectious Diseases. His research has been pivotal in understanding the mechanisms of filovirus entry into cells and the role of lipid rafts during the assembly and budding of these viruses.
Collaborations
Schmaljohn has collaborated with notable colleagues such as Peter M Pushko and Jonathan F Smith, contributing to the advancement of research in the field of infectious diseases.
Conclusion
Alan L Schmaljohn's innovative work in filovirus research has led to significant advancements in vaccine development and therapeutic strategies. His contributions continue to impact the field of virology and public health.